New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
Addition under section:
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
Addition under section:
Baricitinib 2mg tablets and sotrovimab solution for infusion, 500 mg/8 mL (62.5 mg/mL) single use vial, invited for COVID-19.
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
The World Health Organization (WHO), together with the United Nation’s Children Fund (UNICEF) and the United Nations Population Fund (UNFPA), will hold a three-day virtual meeting on 8-10 March 202
Contractual Arrangement: External consultant
Contract Duration: 8 months
Job Posting: Nov 15, 2021, 7:46:07 PM
The WHO list of prequalified in vitro diagnostic products has been updated.
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
Addition under section:
The WHO list of prequalified in vitro diagnostic products has been updated.
Molnupiravir 200 mg capsules for oral administration invited for COVID-19.
The WHO list of prequalified in vitro diagnostic products has been updated.
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
A nitrosamine impurity, 1-methyl-4-nitrosopiperazine (MeNP), was identified in rifampicin products.
A 1st Invitation to Manufacturers of therapeutics against Ebola Virus Disease to submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit is being published by
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
The WHO list of prequalified in vitro diagnostic products has been updated.
Casirivimab and imdevimab combination invited for COVID-19.
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list: